34 completed, 11 unknown, 2 not yet recruiting, 1 recruiting. 24 Phase 1, 10 Phase 2, 7 Phase 3, 4 Phase 4, 2 Not applicable.
Follow Jeil Pharmaceutical Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke Zastaprazan, Placebo - Ischemic Stroke, Transient Ischemic Attack | Phase 3 | Not yet recruiting | Asan Medical Center | 984 | 2026-10-15 | 2026-10-09 |
| Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention Zastaprazan, Rabeprazole - Chronic Coronary Syndrome | Phase 4 | Recruiting | Yonsei University | 100 | 2026-04-02 | 2026-04-24 |
| JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD Erosive Gastroesophageal Reflux Disease | Not yet recruiting | Jeil Pharmaceutical Co., Ltd. | 7150 | 2025-08-25 | 2025-08-14 | |
| Observationa Study is a Prospective and Multi-institutional Observational Study. Erosive Reflux Disease, Heartburn | Completed | Jeil Pharmaceutical Co., Ltd. | 5536 | 2024-11-01 | 2025-05-13 | |
| To Evaluate the Safety, Pharmacokinetic Characteristics and the Effect of Food After Administration of JLP-2004 JLP-2004 qd - Healthy | Phase 1 | Unknown | Jeil Pharmaceutical Co., Ltd. | 36 | 2024-04-23 | 2024-05-28 |
| Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients SGLT2 inhibitor - Type 2 Diabetes Mellitus | Phase 2 | Completed | Jeil Pharmaceutical Co., Ltd. | 161 | 2023-11-03 | 2026-07-07 |
| To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004 JLP-2004, JC-013 - Healthy Adult | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 60 | 2023-10-05 | 2023-12-13 |
| The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole) Lansoprazole 15 mg - Coronary Artery Disease | Phase 4 | Unknown | Daejeon St. Mary's hospital | 300 | 2023-05-01 | 2023-04-19 |
| To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008 SGLT2 inhibitor - Healthy Adult | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 48 | 2022-05-03 | 2023-12-12 |
| To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin JT-003, JT-003 Placebo - Type 2 Diabetes Mellitus | Phase 3 | Unknown | Jeil Pharmaceutical Co., Ltd. | 245 | 2022-04-05 | 2022-03-25 |
| To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JC-001 and JLP-1901 JLP-1901, JC-001(active comparator) - Healthy Adult | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 48 | 2022-02-15 | 2023-12-15 |
| To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin JT-001, JT-001 Placebo - Type 2 Diabetes Mellitus | Phase 3 | Unknown | Jeil Pharmaceutical Co., Ltd. | 256 | 2021-11-17 | 2022-03-07 |
| A Study of Lubiprostone to Treat Constipation No Intervention - Constipation | Unknown | Jeil Pharmaceutical Co., Ltd. | 3000 | 2021-09-01 | 2022-11-17 | |
| The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers JLP-2002, Comparator - Overactive Bladder(OAB) | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 42 | 2021-03-13 | 2021-06-14 |
| Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Characteristics of JP-2266 in Healthy Subjects JP-2266, JP-2266 Placebo - Diabetes Mellitus | Phase 1 | Unknown | Jeil Pharmaceutical Co., Ltd. | 80 | 2020-11-24 | 2021-12-29 |
| To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder JLP-2002 A mg, Placebo - Overactive Bladder | Phase 3 | Completed | Jeil Pharmaceutical Co., Ltd. | 210 | 2020-05-21 | 2022-01-28 |
| The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers JLP-1401, Telmisartan/Amlodipine, Rosuvastatin - Hypertension With Dyslipidemia | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 49 | 2018-12-13 | 2019-08-29 |
| The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers. "Metformin" and "Rosuvastatin" seperately, JLP-1310 - Diabetes, Hyperlipidemias | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 42 | 2018-10-04 | 2019-03-29 |
| Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects Cohort 1 (JP-1366 A mg), Cohort 2 (JP-1366 B mg), Cohort 3 (JP-1366 C mg) - Anti-Ulcer Agents | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 115 | 2017-12-22 | 2019-04-22 |
| A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors JPI-547 - Advanced Solid Tumors | Phase 1 | Completed | Onconic Therapeutics Inc. | 62 | 2017-12-06 | 2022-06-03 |
Showing 20 of 49. Sign in to see all of them.
Diabetes Mellitus (5) · Hyperlipidemias (5) · Urinary Bladder, Overactive (5) · Diabetes Mellitus, Type 2 (4) · Prostatic Hyperplasia (4) · Biliary Tract Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Coronary Artery Disease (2) · Ischemic Stroke (2) · Lower Urinary Tract Symptoms (2) · Stroke (2) · Atherosclerosis (1) · Cigarette Smoking (1) · Constipation (1) · Coronary Aneurysm (1)
Rosuvastatin Calcium (8) · S 1 (combination) (6) · titanium silicide (6) · Amlodipine (5) · Metformin (5) · Telmisartan (5) · Irinotecan (4) · Gemcitabine (3) · JPI-289 (3) · Oxaliplatin (3) · Solifenacin Succinate (3) · Tamsulosin (3) · Atorvastatin (2) · Oxonic Acid (2) · Sodium-Glucose Transporter 2 Inhibitors (2)
South Korea (43) · France (1)
Dae Young Zang, MD, PhD (5) · Kyung-sang Yu, M.D., Ph.D. (2) · Bum Joon Kim, Ph.D. (1) · Dae Young Zang, DM, PhD (1) · DaeWon Kim (1) · Heung Tae Kim, M.D. (1) · Hyeong-Seok Lim, M.D.,Ph.D. (1) · HyeongSeok Lim, M.D.,Ph.D. (1) · Hyo-soo Kim, Professor (1) · Jung-ryul Kim, MD, Ph.D (1) · Kiyuk Chang, M.D. (1) · Kyung-sang Yu, M.D.,Ph.D. (1) · Kyungsoo Park, MD, Ph.D. (1) · Min Gul Kim, MD., Ph.D (1)
PMID 11519503, PMID 15758000, PMID 20925534, PMID 21126648, PMID 22249527, PMID 22688850, PMID 25286881, PMID 26751904, PMID 28886622, PMID 29372461, PMID 29968431, PMID 30522654, PMID 30665829, PMID 30851041, PMID 31152740, PMID 38310875, PMID 41151541, PMID 42270920, PMID 42522372